$MNK (Mallinckrodt Public Limited Company)

$MNK {{ '2016-06-13T12:04:45+0000' | timeago}} • Announcement

$MNK said it submitted Investigational New Drug (IND) application for Synacthen Depot to the U.S. Food and Drug Administration (FDA). The company will pursue an indication for the drug in treatment of Duchenne muscular dystrophy (DMD). $MNK expects continued significant R&D investments in Synacthen Depot as this development program progresses.

$MNK {{ '2017-06-23T12:00:49+0000' | timeago}} • Announcement

$MNK announced new retrospective, claims-based health economic data that show rare, life-threatening disease hepatorenal syndrome (HRS), or the development of renal (kidney) failure in patients with advanced chronic liver disease, imposes a significant economic burden on payers.

$MNK {{ '2017-06-07T12:19:43+0000' | timeago}} • Announcement

$MNK has confirmed enrollment of the first patient in its phase-3 study on StrataGraft regenerative skin tissue, which mimics natural skin, in the promotion of autologous skin regeneration of complex skin defects due to thermal burns that contain intact dermal elements. The study will include patients with 3-49% complex skin defects due to burns.

$MNK {{ '2017-05-24T11:58:11+0000' | timeago}} • Announcement

$MNK confirmed  enrollment of the first patient in its Phase 4 pilot study assessing the efficacy of H.P. Acthar Gel (repository corticotropin injection) for multiple sclerosis relapse. H.P. Acthar Gel is U.S. Food and Drug Administration (FDA)-approved for treatment of acute exacerbations of multiple sclerosis in adults.

$MNK {{ '2017-05-19T21:17:00+0000' | timeago}} • Announcement

$MNK presented facts to refute short-seller claims. Recent media reports have cited allegations by self-acknowledged short sellers whose thesis on $MNK, the company believes, is not based on fact and is intentionally misleading. This statement serves to present facts and correct inaccuracies in those media reports.

$MNK {{ '2017-05-08T18:06:45+0000' | timeago}} • Webcast

$MNK expects SG&A costs to continue to be high into 2Q17, and then see some of that leverage as Mallinckrodt gets into the second half of the year. The company sees second quarter EPS to be more in line with that of 1Q17.

$MNK {{ '2017-05-08T17:49:38+0000' | timeago}} • Webcast

As Mallinckrodt posted its 1Q17 results, $MNK expects its business to expand as a proportion in the Specialty Brands arena in the long-term. The pharma company sees its Specialty Brands business likely growing faster in than the Generics segment.

$MNK {{ '2017-05-08T15:30:24+0000' | timeago}} • Infographic

$MNK Mallinckrodt plc Earnings AlphaGraphics: Q1 2017 highlights

$MNK {{ '2017-05-08T11:11:50+0000' | timeago}} • Announcement

$MNK, which changed its financial period after last quarter results, posted a 4.1% rise in its net sales for the Specialty Brands segment of $557MM in 1Q17. Specialty Generics segment net sales slumped 9.8% to $239MM. Mallinckrodt's cash balance was $260MM at the end of the quarter with its $900MM revolver undrawn.

$MNK {{ '2017-05-08T11:08:09+0000' | timeago}} • Announcement

Net sales of $MNK slipped 0.6% to $811MM in 1Q17, as the biopharma company's net income more than tripled to $399MM from last year's $118MM. Earnings jumped to $3.86 per diluted share from $1.06 a share, while diluted EPS from continuing operations slipped to $0.28 from $088. Income from continuing operations shrunk to $29MM from $99MM a year ago.

$MNK {{ '2017-04-03T13:37:45+0000' | timeago}} • Announcement

$MNK reached an agreement in principle with the U.S. Drug Enforcement Administration (DEA) and the U.S. Attorneys’ Offices (USAOs) for the Eastern District of Michigan and the Northern District of New York. This is to resolve investigations into company monitoring programs for controlled substances. $MNK agreed to pay $35MM to settle past claims.

$MNK {{ '2017-03-20T12:15:38+0000' | timeago}} • Announcement

$MNK said it has closed the sale of its Intrathecal Therapy business to Piramal Enterprises Limited's subsidiary in the U.K., Piramal Critical Care, for approx. $203MM. The transaction will consist of $171MM of fixed consideration of which 10% will be paid at closing, and an additional $154MM will be paid on the first anniversary of the close date.

$MNK {{ '2017-03-01T16:13:13+0000' | timeago}} • Announcement

$MNK said board and management long-term outlook reflected in share repurchase authorization, reinforces its inherent long-term earnings power and free cash generation capabilities. $MNK expects to apply range of capital deployment levers, including strategic, financially sound business development opportunities, and potentially debt reduction.

$MNK {{ '2017-03-01T16:09:13+0000' | timeago}} • Announcement

$MNK BoD authorized an incremental $1Bil repurchase of ordinary shares. The share repurchase program is open-ended in time. $MNK also elected 9 nominees to the BoD, which include Melvin Booth, David Carlucci, Martin Carroll, Diane Gulyas, JoAnn Reed, Angus Russell, Mark Trudeau, Kneeland Youngblood, and Joseph Zaccagnino.

$MNK {{ '2017-02-07T14:47:06+0000' | timeago}} • Webcast

$MNK said it plans to buy more shares during 2017, given the current share price, authorization and liquidity. The company, however, refused to give any specific quantitative levels. At the end of Dec., the company had just north of $260MM on its current authorization program.

$MNK {{ '2017-02-07T14:30:27+0000' | timeago}} • Webcast

For the transitional period, $MNK has published about 25 dataset across its portfolio. Out of the 25 data release, 12 were for Acthar. The company said it has been consistent with the type of volume of data it has generated for the past several quarters and expects that trend to continue in 2017.

$MNK {{ '2017-02-07T14:05:47+0000' | timeago}} • Webcast

During the transition period from Oct. 1, 2016 to Dec. 30, 2016, $MNK generated free cash flow of $130MM. The company said that YoY cash flow for 2017 will decrease due to divestiture and weakness in Specialty Generics.

$MNK {{ '2017-02-07T14:02:02+0000' | timeago}} • Webcast

$MNK expects to be very active with business development during 2017. The company said there are number of highly attractive assets that fits well within its strategic objectives, and it will continue to focus on finding the right assets at the right price.

$MNK {{ '2017-02-07T11:30:08+0000' | timeago}} • Announcement

$MNK expects 2017 adjusted EPS of $7.40-8.00 and total net sales to decrease 2-5%. The company sees Specialty Brands segment net sales to increase 4-7% and Specialty Generics segment net sales to decrease 21-25%. $MNK sees net interest expense of $360-380MM and adjusted effective tax rate of 15-17%.

$MNK {{ '2017-02-07T11:29:53+0000' | timeago}} • Announcement

$MNK slipped to a loss for the transition period ended Dec. 30, 2016 from a profit last year, due to a non-restructuring impairment charge. Net loss was $153.2MM or $1.45 per share compared to a profit of $211.1MM or $1.82 per share last year. Sales grew to $829.9MM from $811.2MM. Adjusted EPS fell to $1.91 from $1.97.

$MNK {{ '2017-02-07T11:29:30+0000' | timeago}} • Announcement

$MNK reported results for transition period from Oct. 1, 2016 to Dec. 30, 2016. The last quarter of CY16 was planned transition period as it aligns to a calendar-based financial year. $MNK will continue its "4/5/4" reporting convention with first FY ending Dec. 29, 2017. The results for transition period are comparable to FY16 ended Dec. 25, 2015.

Recent Transcripts

AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
LGND (Ligand Pharmaceuticals Incorporated)
Tuesday, May 9 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
MNK (Mallinckrodt Public Limited Company)
Monday, May 8 2017 - 12:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, May 4 2017 - 8:30pm
INCY (Incyte Corporation)
Thursday, May 4 2017 - 2:00pm
PCRX (Pacira Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, May 4 2017 - 12:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
BDX (Becton, Dickinson and Company)
Tuesday, May 2 2017 - 12:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm

AlphaGraphics you may like